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Abstract
The β-thalassemias are genetic disorder caused by more than 200 mutations in the β-globin
gene, resulting in a total (β0) or partial (β+) deficit of the globin chain synthesis. The most fre-
quent Mediterranean mutations for β-thalassemia are: β039, β+IVSI-110, β+IVSI-6 and
β0IVSI-1. Several molecular techniques for the detection of point mutations have been
developed based on the amplification of the DNA target by polymerase chain reaction
(PCR), but they could be labor-intensive and technically demanding. On the contrary, Taq-
Man® genotyping assays are a simple, sensitive and versatile method suitable for the single
nucleotide polymorphism (SNP) genotyping affecting the human β-globin gene. Four Taq-
Man® genotyping assays for the most common β-thalassemia mutations present in the Med-
iterranean area were designed and validated for the genotype characterization of genomic
DNA extracted from 94 subjects comprising 25 healthy donors, 33 healthy carriers and 36 β-
thalassemia patients. In addition, 15 specimens at late gestation (21–39 gestational weeks)
and 11 at early gestation (5–18 gestational weeks) were collected from pregnant women,
and circulating cell-free fetal DNAs were extracted and analyzed with these four genotyping
assays. We developed four simple, inexpensive and versatile genotyping assays for the
postnatal and prenatal identification of the thalassemia mutations β039, β+IVSI-110, β+IVSI-
6, β0IVSI-1. These genotyping assays are able to detect paternally inherited point mutations
in the fetus and could be efficiently employed for non-invasive prenatal diagnosis of β-globin
gene mutations, starting from the 9th gestational week.
Introduction
The β-thalassemias are genetic disorder characterized by absence (β0) or reduced (β+) synthesis
of β-globin chains [1–4] associated with a corresponding excess of the complementary α-glo-
bins. The outcome of this unbalanced globin production is the destruction of erythroid precur-
sors in bone marrow and at extramedullary sites (ineffective erythropoiesis) by apoptosis and
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short survival of red blood cells (RBCs) in the peripheral blood [4–6]. The disease is associated
with morbidity and mortality due to severe chronic anemia or treatment-related complica-
tions. The maintenance therapeutic strategies consist of blood transfusion and pharmacologi-
cal chelation, while the only current definitive therapy is bone marrow transplantation is a
definitive therapy [7,8].
More than 200 mutations have been identified in β-thalassemia patients within the β-globin
gene located on chromosome 11, resulting in a total (β0) or partial (β+) deficit of the β-globin
chain synthesis and a subsequent quantitative absence or reduction of the production of adult
HbA hemoglobin [6,7]. The most frequent Mediterranean mutations for β-thalassemia are
β039 (C!T), β+IVSI-110 (G!A), β+IVSI-6 (T!C) and β0IVSI-1 (G!A) [6,7].
The early identification of the pathogenic alteration could be relevant for verifying whether
personalized therapies are available or will be expected to be available, such as the antisense
approach targeting splicing mutations or the read-through approach for nonsense mutations
[9–12]. This would allow responsible decision about possible termination of the pregnancy.
Also, the discrimination of these genetic hereditary mutations could be useful for carrier
parents in view of a targeted prenatal diagnosis.
Several molecular techniques for the detection of point mutations have been developed
based on the preventive amplification of the DNA target by polymerase chain reaction (PCR),
such as restriction fragment length polymorphisms (RFLP-PCR), amplification refractory
mutation system-PCR (ARMS-PCR), high resolution melting-PCR (HRM-PCR), nested-PCR,
DNA sequencing [13]. However, some of these techniques could be labor-intensive and tech-
nically demanding. On the contrary, TaqMan1 genotyping assays are a simple, sensitive and
versatile method suitable for the single nucleotide polymorphism (SNP) genotyping affecting
the human β-globin gene [14].
Moreover non-invasive prenatal diagnosis (NIPD) has become increasingly important,
because, although it retains only a predictive value, it allows investigating fetal health status
without risks for the fetus or the mother and for early therapeutic approach [15]. NIPD is
based on the discovery of circulating cell-free fetal DNA within maternal plasma [16] and,
even though a huge number of studies has been performed to develop experimental
approaches for the detection of fetal abnormalities at an early gestational age, such as nested
PCR, digital PCR, next generation sequencing, MALDI-TOF mass spectrometry, pyropho-
sphorolysis-activated polymerization [17–21], no commercial assays for NIPD are available to
recognize single point mutations, as currently the non-invasive screening tests offered to preg-
nant women can detect only aneuploidies, fetal sex, small deletions or insertions [22–24],
despite the fact that promising studies are available, such as that reported by Yenilmez et al.
[25] and demonstrated to be able to identify non invasively β-thalassemia mutation by HRM
analysis.
The aim of the present investigation is to design, optimize and test specific genotyping
assays in order to detect the four single point mutations in β-globin gene causing β-thalassemia
in the Mediterranean area (β039, β+IVSI-110, β+IVSI-6 or β0IVSI-1) in genomic DNA
extracted from β-thalassemia patients before routine transfusion.
Finally, in order to perform NIPD of fetal thalassemia point mutations inherited from the
father, the four SNP genotyping assays were applied to circulating DNA isolated from preg-
nant women plasma at different gestational ages having normal genotype and carrier partner
for single point mutations in β-globin gene. In fact the identification of paternally-inherited
sequences has been one of the first issues addressed after the discovery of circulating cell-free
fetal DNA in maternal plasma, because its detection is easy and without maternal DNA con-
tamination [24,26].
Genotyping assays for detection of β-thalassemia mutations
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Materials and methods
Samples collection
Blood samples (25 mL) collected from healthy subjects (25), healthy carriers (33) and β-thalas-
semia patients (36) before routinely blood test or transfusion respectively at the Thalassemic
Day Hospital (DHT) of the University Hospital “Sant’Anna” (Cona, Ferrara) and the Hospital
“Santa Maria della Misericordia” (Rovigo) after approval by ethic committees “Comitato Etico
della Provincia di Ferrara”, Italy and “Comitato Etico per la sperimentazione clinica delle
province di Verona e Rovigo”, Italy. In this case participants were between 21 and 42 years old,
105 total approaches, 10% drop-out rate. About 20–25 ml of peripheral blood, were collected
in Vacutainer LH treated tubes (Becton Dickinson), containing EDTA as anticoagulant. For
prenatal experiments, whole peripheral blood (20 mL) from pregnant women (age range: 29–
43 years; total maternal approaches: 27; drop-out rate: 7%) were collected, using test tubes con-
taining EDTA as anticoagulant, in collaboration with the Laboratory of Chemical and Clinical
Analysis and Microbiology, University Hospital “Sant’Anna” (Cona, Ferrara) and after
approval by ethic committee “Comitato Etico della Provincia di Ferrara”, Italy. Peripheral
blood or buccal swabs were obtained by future fathers carrying thalassemia point mutations
and accompanying the future mother for her routinely blood work interested to the project.
The infant buccal swabs were collected from mother that received the swab procedure at the
time of her blood sample and sent us the obtained infant salivary swab after delivery. In all
these cases the informed and written consents were obtained from the mother or father at the
time of taking maternal blood draw previously approval by ethic committee “Comitato Etico
della Provincia di Ferrara”, Italy. Document participant consents were recorded by physician
performed the blood sampling at the University Hospital “Sant’Anna” (Cona, Ferrara) and the
Hospital “Santa Maria della Misericordia” (Rovigo). Baseline demographic characteristics of
the study populations were not recorded. All the experiments were conducted in agreement
with the Declaration of Helsinki.
Genomic DNA extraction
Genomic DNA was extracted from 0.5 ml of blood or two buccal swabs using the QIAamp1
DNA Blood Mini Kit (Qiagen, Hilden, Germany), according to manufacturer’s instructions.
For the blood, 50 μl of Qiagen Protease and 500 μl of buffer AL were added to 500 μl of blood;
after an incubation at 56˚C for 10 minutes and brief centrifugation, 500 μl of 96% ethanol were
mixed to the sample. On the contrary, in the case of buccal swabs, the cotton swab was cut
with a scalpel, and then 400 μl of PBS (Phosphate Buffered Saline), 20 μl of Qiagen Protease
and 400 μl of buffer AL were added; the mixture was incubated at 56˚C for 1 hour and after a
brief centrifugation, 400 μl of 96% ethanol were mixed to the sample. At this point, the same
procedure was applied following the manufacturer’s protocols. Finally the DNA was checked
by agarose-gel electrophoresis, spectrophotometrically quantified, and stored at -20˚C.
Circulating cell-free DNA extraction
Plasma was prepared within 3 hours from 20 mL blood collection, according to the protocol
described in literature [27]. Briefly, after mixing tubes in a rotator for 5–10 minutes, samples
were centrifuged at 1200 x g for 10 minutes at 4˚C without brake. Plasma was then carefully
collected and centrifuged again at 2400 x g for 20 minutes at 4˚C in order to completely
remove platelets and precipitates. The resulting supernatant (6–8 mL) was collected and stored
at -80˚C into single-use 2 mL aliquots. DNA was extracted from 2 ml of maternal plasma, not
thawed more than once, by using the QIAamp1 DSP Virus Spin Kit (Qiagen), according to
Genotyping assays for detection of β-thalassemia mutations
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the manufacturer’s instructions. The availability of several 2 mL aliquots of serum allowed
comparison of different DNA extraction kits and will allow in the future validation of different
mutation detection protocols.
Polymerase Chain Reaction (PCR)
Each reaction was prepared in a final volume of 50 μl, containing ExTaq Buffer (Takara, Otsu,
Shiga, Japan), dNTPs, 150 ng PCR primers, 1.25 U/reaction ExTaq DNA polymerase (Takara).
After a first denaturation step at 94˚C for 2 minutes, amplification cycles included denatur-
ation at 94˚C for 30 seconds, annealing at a 1–2 degrees lower than the melting temperature of
primers for 30 seconds, and elongation at 72˚C for a time proportional to the product length,
taking into account that the enzyme inserts, on average, 1000 bp/minute; at the end, the reac-
tions were maintained at 72˚C for 10 minutes to complete the process of elongation. In each
PCR reaction aimed to DNA sequencing, 100 ng or 30 ng of human genomic DNA obtained
from blood or buccal swabs, respectively, were amplified by using three pairs of primers
(Table 1), in order to include the whole β-globin gene. 0.8 mM dNTPs were employed, and 35
amplification cycles were performed.
PCR products were analyzed by agarose-gel electrophoresis, purified using MicroCLEAN
(Microzone Limited, Haywards Heath, West Sussex, UK) before the DNA sequencing. On the
contrary, in each PCR reaction aimed to pre-amplification for prenatal diagnosis, 1 μl of circu-
lating DNA extracted from maternal plasma was amplified by using a specific pair of primers,
according to the mutation under investigation (Table 2) and in order to increase fetal DNA
template quantity in subsequent genotyping assays.
Table 1. List of primers employed to amplify and sequence the β-globin gene.
Sequence Tm PCR length (bp)
5'-GTGCCAGAAGAGCCAAGGACAGG-3' 72.1˚C 641
5'-AGTTCTCAGGATCCACGTGCA-3' 67.1˚C
5'-GCCTGGCTCACCTGGACA-3' 67.9˚C 954
5'-GTTGCCCAGGAGCTGTGG-3' 67.2˚C
5'-ACAATCCAGCTACCATTCTGCTTT-3' 65.7˚C 436
5'-CACTGACCTCCCACATTCCCTTTT-3' 69.9˚C
The nucleotide sequence and the melting temperature (Tm) are reported for each oligonucleotide. For every pair of primers the length of the respective PCR
product (bp, base pairs) is indicated as well.
doi:10.1371/journal.pone.0172756.t001
Table 2. List of primers employed to amplify circulating DNA in non-invasive prenatal diagnosis experiments.
Sequence Tm PCR length (bp) Mutation
5'-TTAGGCTGCTGGTGGTCTA-3' 55.5˚C 81 β039
5'-CCATAACAGCATCAGGAGTGG-3' 55.4˚C
5'-AGAGAAGACTCTTGGGTTTCTGATAG-3' 55.7˚C 74 β+IVSI-110
5'-GCAGCCTAAGGGTGGGAAA-3' 57.6˚C
5'-CAAGGTGAACGTGGATGAAGTT-3' 55.5˚C 96 β+IVSI-6
5'-CATGCCCAGTTTCTATTGGTCTC-3' 55.7˚C
5'-CAAGGTGAACGTGGATGAAGTT-3' 55.5˚C 105 β0IVSI-1
5'-CTGTCTCCACATGCCCAGTTT-3' 57.6˚C
The nucleotide sequence and the melting temperature (Tm) are reported for each oligonucleotide. For every pair of primers, the length of the respective
PCR product (bp, base pairs) and the relative mutation are also indicated.
doi:10.1371/journal.pone.0172756.t002
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0.4 mM dNTPs were employed, and 30 amplification cycles were performed. Annealing
temperature was 61˚C for primers aimed to detect the β039 mutation, and 55˚C for the other
pairs. 1 μl of PCR product was used as a template for each genotyping assay, without previous
analysis.
TaqMan® genotyping assays
Every reaction was performed in a final volume of 15 μl containing DNA template (1 ng of
genomic DNA or 1 μl of pre-amplification reactions of circulating DNA obtained from mater-
nal plasma), the specific amplification genotyping assay and a PCR Master Mix (Thermo
Fisher Scientific, Waltham, MA, USA). The nucleotide sequences of primers and probes are
reported in Table 3.
All the reactions were performed in duplicate. For each analysis, no-template controls were
prepared as well. The reactions were carried out on a StepOne™ Real-Time PCR System
(Applied Biosystems1—Thermo Fisher Scientific), by using the StepOne Software (Applied
Biosystems1—Thermo Fisher Scientific). After a first 2-minute cycle at 50˚C and a second
10-minute cycle at 95˚C, the amplification cycles were different for each specific genotyping
assay: 50 amplification cycles with denaturation at 95˚C for 15 seconds, and annealing and
elongation at 62˚C for 1 minute for β039, β+IVSI-110 and β+IVSI-6 assays; 60 amplification
cycles with denaturation at 95˚C for 15 seconds, and annealing and elongation at 60˚C for 1
minute for β0IVSI-1. Since each reaction was performed in duplicate, the average Rn value was
calculated for each sample. For each genotyping assay, final VIC1 and FAM™ Rn values were
plotted in an allelic discrimination plot.
For analysis of genomic DNA, the end-point fluorescence produced by VIC1 and FAM™
was normalized with the ROX™ reference, according to the following equations: VIC1
Rn = VIC1/ROX™; FAM™ Rn = FAM™/ROX™.
Table 3. List of oligonucleotides used as primers or probes for genotyping experiments.
Sequence Primer/Probe Mutation
5'-CTTAGGCTGCTGGTGGTCTAC-3' Forward primer β039
5'-AGTGGACAGATCCCCAAAGGA-3' Reverse primer
5'-AAGAACCTCTGGGTCCAA-3' VIC® probe
5'-CAAAGAACCTCTAGGTCCAA-3' FAM™ probe
5'-GGGTTTCTGATAGGCACTGACT-3' Forward primer β+IVSI-110
5'-GCAGCCTAAGGGTGGGAAA-3' Reverse primer
5'-CTCTGCCTATTGGTCTAT-3' VIC® probe
5'-TCTCTGCCTATTAGTCTAT-3' FAM™ probe
5'-GTGAACGTGGATGAAGTTGGT-3' Forward primer β+IVSI-6
5'-CTATTGGTCTCCTTAAACCTGT-3' Reverse primer
5'-CTTGTAACCTTGATACCAACC-3' VIC® probe
5'-TGTAACCTTGATGCCAACC-3' FAM™ probe
5'-GTGAACGTGGATGAAGTTGG-3' Forward primer β0IVSI-1
5'-CCCAGTTTCTATTGGTCTCCTTA-3' Reverse primer
5'-TGGGCAGGTTGGTA-3' VIC® probe
5'-TGGGCAGATTGTAT-3' FAM™ probe
The nucleotide sequence and the relative investigated mutation are reported.
doi:10.1371/journal.pone.0172756.t003
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DNA sequencing
β-globin PCR products obtained using, as target, genomic DNA from healthy donors, healthy
carriers, hemoglobinopathy patients, future fathers, or from babies, were sequenced according
to Sanger’s method [28] with primers reported in Table 1. Sequence reactions were performed
in final volume of 20 μl, containing 40–90 ng of PCR template, 3.2 pmol of sequencing primer
and ultrapure water to a 12 μl volume. Then 8 μl of Terminator Ready Reaction Mix of ABI
PRISM1 BigDye™ Terminator Cycle Sequencing Ready Reaction Kit (Thermo Fisher Scien-
tific), were added, containing the four differently-labeled dideoxyribonucleotides (ddNTPs),
the AmpliTaq1 DNA polimerase, MgCl2 and Tris-HCl buffer at pH 9.0. A total of 45 amplifi-
cation cycles were performed, as follows: denaturation, 96˚C, 10 s; annealing, 65˚C, 5 s; elonga-
tion, 65˚C, 3 min. The reaction products were then purified from unincorporated ddNTPs by
using a 96-well MultiScreen™ (Merck Millipore, Billerica, MA, USA) plate: after loading on
pre-hydrated wells filled with Sephadex™ G-50 Superfine (GE Healthcare, Little Chalfont, UK),
samples were recovered by centrifugation at 900 x g for 6 minutes and dried under vacuum.
Sequencing was finally performed by BMR Genomics (Padova, Italy), while the obtained
sequence data were analyzed by the Sequence Scanner, version 1.0 (Applied Biosystems1—
Thermo Fisher Scientific), software.
Results
Genotyping assays for the detection of β-thalassemia point mutations in
genomic DNA
The first aim of this work was the development of a postnatal approach for molecular diagnosis
of β-thalassemia point mutations based on TaqMan1 genotyping assays.
This approach was already presented in a previous study by Alwazani et al. [14]; this study
was, however, not focused on NIPD.
Each custom assay contains two primers, able to recognize and amplify both the normal
and the mutated sequence, and two differently labeled TaqMan1 probes: a probe specific for
the normal sequence, labeled at the 5’ end with VIC1 (4,7,2’-trichloro-7’phenyl-6-carboxy-
fluorescein), and a FAM™ (6-carboxy-fluorescein)-conjugated probe able to hybridize with the
mutated sequence [29]; at the 30 end, both the probes are coupled with the quencher NFQ, a
non-fluorescent quencher acting as energy transfer acceptor [30].
We designed four genotyping assays for the detection of the most common Mediterranean
mutations for β-thalassemia in genomic DNA extracted from blood or buccal swabs of 94
donors with different clinical conditions.
We prepared 25 samples from healthy subjects, 33 samples from healthy carriers and 36
samples from β-thalassemia patients with homozygous or heterozygous genotype for the four
mutations, all confirmed by DNA sequencing (Fig 1 and Table 4). Each sample was analyzed
by all four single-plex genotyping assays specific for one of the β-thalassemia single point
mutation.
In particular Fig 1 reports the allelic discrimination plots generated by the genotyping
assays specific for β039 (A), β+IVSI-110 (B), β+IVSI-6 (C), β0IVSI-1 (D). All the diagrams show
that the samples are arranged into three major and distinct groups in the allelic discrimination
plot: samples from healthy subjects (N/N), having a high value of VIC1 fluorescence and a
low value of FAM™ fluorescence, are arranged in the lower right position; in contrast homozy-
gous samples for a specific mutation (Mut/Mut), are arranged in the upper left position char-
acterized by high FAM™ and low VIC1 fluorescence values, respectively. Finally, samples from
healthy carriers (N/Mut) and double heterozygous subjects (Mut/Mut), giving similar values
Genotyping assays for detection of β-thalassemia mutations
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of FAM™ and VIC1 fluorescences, are placed in the middle. We never observed exceptions to
this discrimination results and genotype-associated patterns.
In addition, in all cases no differences were found among results obtained by DNA samples
purified by blood or buccal swabs (data not shown), indicating that the latter may be consid-
ered a very interesting simple and non-invasive alternative to blood sampling as a source of
genomic DNA for molecular diagnosis.
Fig 1. Allelic discrimination plots obtained from 94 total samples of genomic DNA. The genomic DNAs extracted from healthy donors, healthy
carriers and β-thalassemia patients, were analyzed with β039 (A), β+IVSI-110 (B), β+IVSI-6 (C), or β0IVSI-1 (D) genotyping assays. For each plot, the
normalized end-point fluorescence (Rn) values generated by the VIC®-labeled probe for the normal allele and the FAM™-labeled probe for the mutated
allele are reported along the x-axis and the y-axis, respectively.
doi:10.1371/journal.pone.0172756.g001
Genotyping assays for detection of β-thalassemia mutations
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Genotyping assays for the detection of β-thalassemia point mutations in
circulating cell-free fetal DNA
Twenty-six samples of circulating fetal DNA obtained from pregnant women at different ges-
tational ages with father carrier of β-thalassemia were analyzed by TaqMan1 genotyping
assays (Figs 2 and 3 and Table 5). In particular, we collected 15 specimens at late gestation
(21–39 gestational weeks) and 11 specimens at early gestation (5–18 gestational weeks), in
order to test the assay sensitivity, as the concentration of cell-free fetal circulating DNA raises
in maternal circulation with increasing gestational age [31].
In order to identify the mutations of the β-globin gene of carrier fathers, a buccal swab or a
blood sample was collected from the future father and genomic DNAs were extracted and
sequenced to identify the specific genotype.
In our case, the identified mutations cover the most common Mediterranean alterations
causing β-thalassemia, and also within this small group of samples, the relative frequency is the
same: the majority of fathers carried the β039 mutation, a lower number the β+IVSI-110 and
only a few the β0IVSI-1 and β+IVSI-6 mutations (Table 5).
As reported in literature [22–26], the detection of fetal mutations inherited from the father
should be quite feasible because they are not present in maternal DNA, that is the main com-
ponent of circulating DNA extracted from maternal plasma. In the case of genotyping assays,
with mutation transmitted by the father, maternal circulating DNA does not carry the mutated
sequence (the mother’s genotype is N/N) and so will be amplified only by the VIC1-labeled
probe complementary to the normal sequence. Therefore, if the fetus is N/N like the mother,
only an amplification signal from the VIC1-labeled probe is expected; while if the fetus has
inherited the father’s mutation, his circulating DNA, in addition to be amplified by the normal
VIC1-labeled probe, will be recognized also by the FAM™-labeled probe carrying the mutated
sequence. In conclusion, the generation of a FAM™ fluorescence signal, related to the presence
of a mutated allele, should occur only in the case the fetus has inherited the father’s mutation.
Table 4. List of β-globin allele genotypes resulting by genotyping assays.
Analyzed subjects Genotype No. samples
Healthy donors N/N 25
Healthy carriers β039/N 11
β+IVSI-110/N 11
β+IVSI-6/N 7
β0IVSI-1/N 4
β-thalassemia patients β039/β039 8
β+IVSI-110/β+IVSI-110 8
β+IVSI-6/β+IVSI-6 5
β0IVSI-1/β0IVSI-1 1
β+IVSI-6/β+IVSI-110 2
β+IVSI-110/β039 3
β0IVSI-1/β039 3
β+IVSI-6/β039 2
β+IVSI-110/β0IVSI-1 1
β+IVSI-6/β0IVSI-1 3
The analysis was performed for 94 total samples of genomic DNA from healthy donors, healthy carriers and
β-thalassemia patients. For each genotype, the number of samples deriving from blood or buccal swabs is
indicated as well.
doi:10.1371/journal.pone.0172756.t004
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Moreover fetal DNA represents a small portion of the total circulating DNA ranging
between 3 and 6% [32], despite the fact that a percentage close to 10–20% in the last weeks of
gestation has been recently reported [31,33]. To overcome this drawback and avoid false nega-
tive results, we assayed a pre-amplification approach aimed to increase the target fetal
sequences before the genotyping assays. Circulating DNA sample, after pre-amplification, was
analyzed using the genotyping assay specific for the relative father’s mutation and the identi-
fied fetal genotype was confirmed by sequencing the newborn genomic DNA obtained from
buccal swab (Table 5).
With respect to the β039 mutation, 15 samples from pregnant women at different gesta-
tional ages having β039 carrier fathers were collected. The FAM™-labeled mutated probe
allowed to identify mutated alleles for all samples, suggesting a heterozygous β039/N fetal
genotype, except for four samples (#142, #141, #136, #147), where no mutated curves were
detectable in accordance with a N/N genotype (Fig 2A).
All the identified fetal genotypes were confirmed except for the sample #142 (Table 5). In
this case, the actual baby’s genotype was β039/N, but no mutated curve was obtained by
Fig 2. Amplification curves obtained by β039 or β+IVSI-110 genotyping assays from circulating DNA extracted from maternal plasma. Real-time
PCR with β039 (A) or β+IVSI-110 (B) genotyping assays, containing a normal probe (VIC®, upper panels) and a mutated probe (FAM™, lower panels)
were performed for circulating DNA extracted from maternal plasma where the father was a carrier of β039 (A) or β+IVSI-110 (B) thalassemia mutation,
respectively. The plots show the ΔRn values as a function of the number of amplification cycles, while the threshold line is drawn in blue. Samples are
listed according to increasing gestational ages. In panel (B), #146a and #146b refer to samples collected from the same pregnant woman (number 146) at
different gestational ages: 5 weeks and 10 weeks, respectively. The amplification was performed by using the StepOne™Real-Time PCR System
(Applied Biosystems®—Thermo Fisher Scientific).
doi:10.1371/journal.pone.0172756.g002
Genotyping assays for detection of β-thalassemia mutations
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genotyping assay (Fig 2A). Perhaps this depends on the too low amount of fetal DNA in the
specimens collected at early stage pregnancy (5 gestational weeks).
The same problem occurred in the β+IVSI-110 diagnosis, where no mutation-dependent
signals were produced by sample #146a at the 5th gestational week, in contrast with the relative
β+IVSI-110/N genotype obtained after postnatal baby’s DNA sequencing (Table 5). While the
same sample collected at the 10th gestational week (#146b) showed the correct fetus’ genotype,
confirming that the circulating cell-free fetal DNA at 5 gestational weeks is really scarce for a
correct detection by genotyping assay. As for the other six samples, the FAM™-labeled mutated
probe allowed to identify mutated alleles only for samples #172, #236 and #140, suggesting het-
erozygous β+IVSI-110/N genotypes and normal genotypes for the other three samples (#43,
#138, #207) (Fig 2B). All these fetus genotypes were confirmed after sequencing of the child’s
genomic DNA from buccal swabs, except for sample #236 due to not obtaining of buccal
swabs of father and infant (Table 5).
Unfortunately, for the β+IVSI-6 and β0IVSI-1 mutations, only one and two samples were
available, respectively. For the mutation β+IVSI-6 the only sample #137 was analyzed. The pre-
amplified circulating DNA generated detectable amplification curves with both normal and
Fig 3. Amplification curves obtained by β+IVSI-6 or β0IVSI-1 genotyping assays from circulating DNA extracted from maternal plasma. Real-
time PCR with β+IVSI-6 (A) or β0IVSI-1 (B) genotyping assays, containing a normal probe (VIC®, upper panels) and a mutated probe (FAM™, lower
panels), were performed for circulating DNA extracted from maternal plasma where the father was a carrier of β+IVSI-6 (A) or β0IVSI-1 (B) thalassemia
mutation, respectively. The plots show the ΔRn values as a function of the number of amplification cycles, while the threshold line is drawn in blue.
Samples are listed according to increasing gestational ages. The amplification was performed by using the StepOne™Real-Time PCR System (Applied
Biosystems®—Thermo Fisher Scientific).
doi:10.1371/journal.pone.0172756.g003
Genotyping assays for detection of β-thalassemia mutations
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mutated probes (Fig 3A); therefore we could propose the heterozygous β+IVSI-6/N genotype
of a β-thalassemia carrier: this diagnosis is still waiting for confirmation because the buccal
swab of the child has not obtained yet (Table 5). For the β0IVSI-1 mutation, all mutated alleles
were identified by the FAM™-labeled mutated probe (Fig 3B), showing for both samples het-
erozygous β0IVSI-1/N genotypes, as confirmed by sequencing the newborns’ genomic DNAs
(Table 5).
Table 5. List of samples of circulating DNA extracted from maternal plasma with father carrier for β thalassemia point mutation, analyzed by the
specific genotyping assay.
β039 mutation
# sample Gestational age (weeks) Father’s genotype Formulated diagnosis Fetus‘ genotype Diagnosis outcome
142 5 β039/N N/N β039/N Wrong
62 13 β039/N β039/N β039/N Confirmed
178 14 β039/N β039/N β039/N Confirmed
61 21 β039/N β039/N β039/N Confirmed
141 22 β039/N N/N N/N Confirmed
136 23 β039/N N/N N/N Confirmed
147 24 β039/N N/N N/N Confirmed
287 24 β039/N β039/N β039/N Confirmed
132 25 β039/N β039/N β039/N Confirmed
31 26 β039/N β039/N β039/N Confirmed
36 28 β039/N β039/N β039/N Confirmed
186 29 β039/N β039/N β039/N Confirmed
193 33 β039/N β039/N β039/N Confirmed
217 35 β039/N β039/N β039/N Confirmed
265 39 β039/N β039/N β039/N Confirmed
β+IVSI-110 mutation
# sample Gestational age (weeks) Father’s genotype Formulated diagnosis Fetus‘ genotype Diagnosis outcome
146a 5 β+IVSI-110/N N/N β+IVSI-110/N Wrong
172 9 β+IVSI-110/N β+IVSI-110/N β+IVSI-110/N Confirmed
146b 10 β+IVSI-110/N β+IVSI-110/N β+IVSI-110/N Confirmed
236 10 β+IVSI-110/N β+IVSI-110/N n.d. n.d.
140 15 β+IVSI-110/N β+IVSI-110/N β+IVSI-110/N Confirmed
43 18 β+IVSI-110/N N/N N/N Confirmed
138 37 β+IVSI-110/N N/N N/N Confirmed
207 37 β+IVSI-110/N N/N N/N Confirmed
β+IVSI-6 mutation
# sample Gestational age (weeks) Father’s genotype Formulated diagnosis Fetus‘ genotype Diagnosis outcome
137 11 β+IVSI-6/N β+IVSI-6/N n.d. n.d.
β0IVSI-1 mutation
# sample Gestational age (weeks) Father’s genotype Formulated diagnosis Fetus‘ genotype Diagnosis outcome
134 17 β0IVSI-1/N β0IVSI-1/N β0IVSI-1/N Confirmed
151 28 β0IVSI-1/N β0IVSI-1/N β0IVSI-1/N Confirmed
The father was a carrier of β039, β+IVSI-110, β+IVSI-6 or β0IVSI-1 thalassemia mutation, analyzed with the specific β039, β+IVSI-110, β+IVSI-6 or β0IVSI-1
genotyping assay. Samples are listed according to increasing gestational ages. #146a and #146b refer to samples collected from the pregnant woman #146
at 5 and 10 gestational weeks, respectively. The father genotype, the fetus genotype, the formulated diagnosis by genotyping assays and the diagnosis
outcome are reported. n.d., not determined.
doi:10.1371/journal.pone.0172756.t005
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Discussion
Hemoglobin disorders are recognized among the most common inherited diseases worldwide.
Approximately 7% of the world population currently exhibits symptoms of hemoglobinopa-
thies, including β-thalassemia. The early identification of the pathogenic molecular alterations
could be useful for verifying whether personalized therapies are available or will be expected to
be available allowing responsible decision about possible termination of the pregnancy, as well
as the active search of clinicians those personalized interventions.
Several techniques based on polymerase chain reaction (PCR) or genomic sequencing are
currently used for molecular diagnosis of thalassemia, but they are labor-intensive and time-con-
suming in performing the assays and analyzing the results. On the contrary, rapid and accurate
molecular techniques are essential for detection of thalassemia mutations in affected families.
In this context, the TaqMan1 genotyping assay represents a reliable, sensitive and cost-
effective diagnostic method allowing the discrimination of single nucleotide polymorphisms
[34,35]. Thus, the TaqMan1 genotyping assay is suitable for large-scale screenings and high-
throughput analyses. The simplicity and reproducibility of the assay permit its use in laborato-
ries as a rapid (it allows detection of mutations in less than 40 minutes) and inexpensive diag-
nostic tool for mutations diagnosis [35].
It requires two subsequent steps: a first amplification by PCR or real-time PCR, in the pres-
ence of suitable probes, followed by the detection of the end-point resulting signals. To distin-
guish the two different alleles, a pair of allele-specific oligonucleotide probes are used, one
complementary to the normal sequence and the other specific for the mutated one, marked
with different fluorescent labels.
TaqMan1 genotyping assays were designed for characterization of β-thalassemia mutations
in the Malays and Kingdom of Saudi Arabia [14,34–36]. Also, an analogous TaqMan1 assay
was developed and reported to be effective for detection of the Sardinian Wilson’s mutation
[37]. In addition, TaqMan1 genotyping probes can be designed to detect also multiple nucleo-
tide polymorphisms and insertions/deletions. For example, this approach has been suggested
as a rapid and reliable assay for genotyping of different α-globin gene deletions, also applicable
to mass screening for probable carriers [38].
In this work, we designed four TaqMan1 genotyping assays for the most common β-thalas-
semia mutations in the Mediterranean area (β039, β+IVSI-110, β+IVSI-6, β0IVSI-1). The differ-
ent genotypes of 36 thalassemia patients were characterized using these assays and all
confirmed by DNA sequencing. In addition, the TaqMan1 genotyping assays for the β039,
β+IVSI-110, β0IVSI-1 mutations in thalassemia patients have been recently validated for the
detection of the three genetic variants in patients from western region of the Kingdom of
Saudi Arabia [14]. However these reports were focused on post-natal diagnostic approaches,
while the results presented in this paper appears to retain considerable interest in the filed of
rapid prenatal screening.
In recent years, several non-invasive approaches based on the detection of circulating cell-
free fetal DNA in maternal plasma have been developed to carry out prenatal diagnosis [17–
21,39], but currently, commercial non-invasive prenatal screening tests are very expensive,
besides requiring technical expertise and complex equipment and infrastructure. In addition,
they only allow the detection of fetal sex and the most common aneuploidies, but not point
mutations causing genetic disorders [33,40–42].
In this context, genotyping assays could be an alternative and robust tool for the genetic
diagnosis of single point mutations causing genetic diseases such as thalassemia.
Therefore we applied the four genotyping assays to non-invasive prenatal detection of thal-
assemia fetal point mutations inherited from the father, because fetal paternally-inherited
Genotyping assays for detection of β-thalassemia mutations
PLOS ONE | DOI:10.1371/journal.pone.0172756 February 24, 2017 12 / 16
sequences in maternal plasma present relative easiness of detection as they are not present in
maternal contaminating DNA [22–26].
The fraction of circulating cell-free fetal DNA in maternal plasma is a critical parameter for
genetic screening with non-invasive prenatal testing, especially at the earlier gestational age.
Based on these considerations, we performed a pre-amplification step before the genotyping
assays in order to avoid false negative results and increase target fetal sequences.
Our results indicate that the developed genotyping assays are able to detect paternally-
inherited point mutations in the fetus, and could be efficiently employed for non-invasive pre-
natal diagnosis of β-globin gene mutations, starting from the 9th gestational week. The
obtained data demonstrated that genotypic discrimination at earlier gestational ages (< 5th
week) by genotyping assays was prevented, probably due to the very low amount of fetal circu-
lating DNA.
Since circulating fetal DNA is detectable in maternal plasma from 4th-5th week of gestation
[43], the improvement of DNA extraction and enrichment procedures [44,45] could be pro-
posed in order to apply genotyping assays in earlier phases of gestation.
It should be mentioned that alternative, but costly, novel technologies could be proposed,
such as digital PCR. For this technology, the discrimination of possible fetal mutations is
apparently not prevented by the maternal DNA background [46,47]. Accordingly, a compari-
son of the two approaches should be considered in future experimental planning. Moreover, it
will be useful the increasing of the analyzed samples, especially at early gestation, to estimate
the detection limit of the technique and the application of this approach to other thalassemia
or sickle cell anemia mutations.
Conclusions
We developed and validated four simple, inexpensive and versatile genotyping assays for the
postnatal and prenatal identification of the most common Mediterranean mutations causing
β-thalassemia: β039, β+IVSI-110, β+IVSI-6, β0IVSI-1. The developed genotyping assays are able
to detect paternally-inherited point mutations in the fetus, and could be efficiently employed
for non-invasive prenatal diagnosis of β-globin gene mutations, starting from the 9th gesta-
tional week. It should be useful the increasing of the analyzed samples, especially at early gesta-
tion, to estimate the detection limit of the technique and the application of this approach to
other thalassemia or sickle cell anemia mutations.
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